Abstract
Initially launched in 2008 for primary prevention of post-operative venous thromboembolism (VTE), direct oral anticoagulants (DOACs) represent a major advancement in anticoagulation[1–4]. The number of licensed DOACs and indications has now increased to include treatment or recurrence of deep vein thrombosis, pulmonary embolism and thromboprophylaxis of stroke in patients with atrial fibrillation (AF)[2–11]. Compared with […]
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call